Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells

Keiji Yoshinaga, Keishi Yamashita, Koshi Mimori, Fumiaki Tanaka, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.

Original languageEnglish
Pages (from-to)96-103
Number of pages8
JournalAnnals of Surgical Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Carcinoma
Neoplasms
Cell Line
Activins
Apoptosis
Carcinogenesis
Esophageal Squamous Cell Carcinoma
activin A
Squamous Cell Neoplasms
Esophageal Neoplasms
Growth
Neutralizing Antibodies
Heterografts
Lymph Nodes
Neoplasm Metastasis
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. / Yoshinaga, Keiji; Yamashita, Keishi; Mimori, Koshi; Tanaka, Fumiaki; Inoue, Hiroshi; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 15, No. 1, 01.01.2008, p. 96-103.

Research output: Contribution to journalArticle

Yoshinaga, Keiji ; Yamashita, Keishi ; Mimori, Koshi ; Tanaka, Fumiaki ; Inoue, Hiroshi ; Mori, Masaki. / Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. In: Annals of Surgical Oncology. 2008 ; Vol. 15, No. 1. pp. 96-103.
@article{cd5044d076c44f5e87d44d28206acd5f,
title = "Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells",
abstract = "Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.",
author = "Keiji Yoshinaga and Keishi Yamashita and Koshi Mimori and Fumiaki Tanaka and Hiroshi Inoue and Masaki Mori",
year = "2008",
month = "1",
day = "1",
doi = "10.1245/s10434-007-9631-1",
language = "English",
volume = "15",
pages = "96--103",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells

AU - Yoshinaga, Keiji

AU - Yamashita, Keishi

AU - Mimori, Koshi

AU - Tanaka, Fumiaki

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.

AB - Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.

UR - http://www.scopus.com/inward/record.url?scp=38049152697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049152697&partnerID=8YFLogxK

U2 - 10.1245/s10434-007-9631-1

DO - 10.1245/s10434-007-9631-1

M3 - Article

C2 - 17909904

AN - SCOPUS:38049152697

VL - 15

SP - 96

EP - 103

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -